All Articles

Compal Electronics is doubling down on high-density liquid cooling and intelligent management in its new AI server line, aiming to drastically reduce energy consumption and boost performance for demanding workloads.

Biotech firm TG Therapeutics secures a spot on Deloitte’s Technology Fast 500, fueled by strong sales of its MS treatment, BRIUMVI. Analysts assess the company's trajectory and potential in a competitive market.

Facing rating downgrades & operational headwinds, Baxter International is restructuring its debt. Is this a sign of strength or a necessary correction? We delve into the company’s financial strategy & industry outlook.

A new partnership aims to extend critical care beyond the hospital walls, leveraging FDA-cleared technology to improve outcomes for vulnerable infants and ease the burden on healthcare systems.

A new Natixis survey reveals growing anxiety among institutional investors about a potential market correction in 2026, prompting a re-evaluation of risk and a move towards more diversified portfolios.

A new partnership fuels the growth of experiential travel with investments in unique outdoor destinations, signaling a shift towards curated adventure and sustainable tourism.

Investment in Friedreich’s Ataxia (FA) treatments is surging, driven by promising gene therapies and small-molecule innovations. A new report signals a robust future for this rare disease market, but challenges remain.

Facing financial headwinds, Tempest Therapeutics is making a bold move into cell therapy with the all-stock acquisition of Factor Bioscience. The deal extends the company's cash runway and reshapes its pipeline, but analysts question the valuation.

National Yang Ming Chiao Tung University’s (NYCU) groundbreaking research in AI, fintech, and sustainability earns it the WRDS Innovation Award, highlighting Asia’s growing influence in global innovation.

As AI-powered deepfakes become increasingly sophisticated, Pindrop Pulse offers a critical layer of security for video conferencing. A closer look at the technology combating real-time impersonation and protecting businesses from mounting fraud.

New report identifies overlooked locations offering specialized life sciences talent, challenging the industry's reliance on established hubs. AI-driven insights reveal cost-effective alternatives for workforce expansion.

Medical imaging innovator Nanox Imaging acquires VasoHealthcare IT to accelerate US deployment of its AI-powered diagnostics. The deal signals a shift towards integrated solutions in a rapidly evolving market.

MDVIP's expansion into Central Vermont reflects a growing trend toward personalized, preventative care. But can this membership model address rural healthcare challenges and remain accessible to all?

A pivotal Phase 3 trial for Oncolytics Biotech’s immunotherapy, pelareorep, has received FDA alignment, offering a potential new weapon against one of the most aggressive cancers. The move signals progress in converting ‘cold’ tumors into those receptive to immunotherapy.

A deepened partnership between Microsoft and CrashPlan aims to alleviate ballooning Microsoft 365 storage expenses and unlock new potential from backup data with AI-powered search capabilities.

Small-cap biotech RenovoRx presents at an investor showcase amid Phase III trial progress and growing competition in targeted cancer therapies. Is the company’s TAMP platform poised for disruption?

Pharmaceutical giant Teva launches a global open innovation platform, ‘Teva Rise,’ aiming to accelerate advancements in AI, digital health, and smart manufacturing. The move signals a strategic shift toward collaborative R&D.

The recent $5.2M sale of a Sleep Inn & Suites in Valdosta, GA, highlights ongoing investor confidence in well-positioned midscale hotels and a thriving Southeast tourism sector. Strategic renovations played a key role in the deal.

New funding fuels RapidSOS’s expansion of its AI-powered platform connecting millions of devices to 22,000+ public safety agencies, accelerating a shift towards faster, data-driven emergency response.

Positive interim data from Protara Therapeutics’ Phase 2 trial of TARA-002 offers hope for pediatric patients with lymphatic malformations, a rare disease with limited effective therapies. The company’s cell-based approach builds on an established Japanese treatment.